ProShare Advisors
OLMA icon

ProShare Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

ProShare Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Sell
13,136
-574
-4% -$7.69K ﹤0.01% 1688
2026
Q1 		$204K Sell
13,710
-657
-5% -$14.6K ﹤0.01% 1568
2025
Q4 		$359K Buy
14,367
+1,740
+14% +$31K ﹤0.01% 1343
2025
Q3 		$124K Sell
12,627
-2,139
-14% -$12.8K ﹤0.01% 1807
2025
Q2 		$62.9K Buy
14,766
+2,569
+21% +$11.5K ﹤0.01% 1965
2025
Q1 		$45.9K Sell
12,197
-2,029
-14% -$10.2K ﹤0.01% 1962
2024
Q4 		$82.9K Buy
14,226
+3,298
+30% +$32.9K ﹤0.01% 2105
2024
Q3 		$130K Buy
+10,928
New +$140K ﹤0.01% 1841
2022
Q1 		– Sell
-11,173
Closed -$105K – 2270
2021
Q4 		$105K Buy
+11,173
New +$231K ﹤0.01% 2197

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

ProShare Advisors's OLMA Position: Q2 2026 in Review

ProShare Advisors reduced its Olema Pharmaceuticals (OLMA) stake by 4.2% in Q2 2026, selling an estimated $7.69K and leaving 13,136 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #1688.

ProShare Advisors first reported a position in OLMA in Q4 2021 and has held it in 9 quarters since. The position peaked at $359K in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • ProShare Advisors held 13,136 shares of Olema Pharmaceuticals worth $164K as of Q2 2026.
  • ProShare Advisors sold 574 Olema Pharmaceuticals shares in Q2 2026, an estimated $7.69K.
  • Olema Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1688 holding.
  • ProShare Advisors first reported a position in Olema Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
  • ProShare Advisors's Olema Pharmaceuticals position peaked at $359K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.